SHELBY CHAMBERLAIN: Open Payments
NPI 1568134161 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 34 payments from 9 companies in 2025. Trend: 2023 $116 · 2024 $198 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 12 | $275 |
| PFIZER INC. | 6 | $126 |
| AstraZeneca Pharmaceuticals LP | 4 | $86 |
| Astellas Pharma US Inc | 4 | $85 |
| ABBVIE INC. | 2 | $54 |
| Eisai Inc. | 2 | $49 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Fennec Pharmaceuticals, Inc. | 1 | $17 |
Products named: LYNPARZA, TIVDAK, KEYTRUDA, Veozah, ELAHERE, Lenvima, JEMPERLI, MYFEMBREE.
Industry payments across AL — which companies pay providers there.
